Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, D. P.
Right arrow Articles by Demetri, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, D. P.
Right arrow Articles by Demetri, G. D.
The Oncologist, Vol. 7, No. 6, 531–538, December 2002
© 2002 AlphaMed Press

A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors

David P. Ryana, Thomas Puchalskia, Jeffrey G. Supkoa, David Harmona, Robert Makib, Rocio Garcia-Carboneroa,c, Caroline Kuhlmana, Jennifer Winkelmana, Priscilla Merriamc, Travis Quigleyc, Jose Jimenod, Judith Manolac, George D. Demetric

a Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; b Division of Adult Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; c Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; d Pharma Mar, S.A., Madrid, Spain

Correspondence: David P. Ryan, M.D., MGH Cancer Center, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114, USA. Telephone: 617-724-4000; Fax: 617-724-3166; e-mail: dpryan{at}partners.org

Purpose. To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs).

Patients and Methods. The study was confined to adult patients with radiographically measurable GISTs. ET-743 was administered as a 24-hour continuous i.v. infusion at a dose of 1.5 mg/m2 repeated every 3 weeks. Pharmacokinetic blood sampling was performed during the first cycle of therapy. Tumors were restaged after every second cycle of therapy.

Results. A total of 20 patients was enrolled in the study, 19 of whom were treated with 47 cycles of ET-743 (median 2, range 1-10). Severe toxicities were limited to reversible grade 3 transaminitis in 10 patients and grade 3 fatigue in one patient. There were no objective responses, and disease stabilization occurred in two patients lasting for periods of 4 and 10 months. The 1-year survival rate was 71.1%. Mean ± standard deviation values of the maximum plasma concentration and total plasma clearance were 1.1 ± 0.4 ng/ml and 44 ± 16 l/h/m2, respectively, for 19 of the 20 patients.

Conclusion. This study is the first report of a prospective phase II trial to evaluate a cytotoxic agent in patients with GISTs. This study underscores the primary resistance of GISTS to chemotherapy and stands in stark contrast to the encouraging results recently achieved with STI571. The lack of response may be associated with a therapeutically ineffective exposure to the drug based upon the lower incidence of severe toxicities and greater clearance than described in phase I and II trials of ET-743.

Key Words. Cancer • Chemotherapy • Clinical trials • Human studies • c-kit




This article has been cited by other articles:


Home page
 The OncologistHome page
R. S. Benjamin, C. D. Blanke, J.-Y. Blay, S. Bonvalot, and B. Eisenberg
Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies
Oncologist, January 1, 2006; 11(1): 9 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Theou, S. Gil, A. Devocelle, C. Julie, A. Lavergne-Slove, A. Beauchet, P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, et al.
Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib
Clin. Cancer Res., November 1, 2005; 11(21): 7593 - 7598.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-Y. Blay, S. Bonvalot, P. Casali, H. Choi, M. Debiec-Richter, A. P. Dei Tos, J.-F. Emile, A. Gronchi, P. C. W. Hogendoorn, H. Joensuu, et al.
Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
Ann. Onc., April 1, 2005; 16(4): 566 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Lau, J. G. Supko, S. Blaney, L. Hershon, N. Seibel, M. Krailo, W. Qu, D. Malkin, J. Jimeno, M. Bernstein, et al.
A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study
Clin. Cancer Res., January 15, 2005; 11(2): 672 - 677.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.
Advertisement